Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.
|
23246288 |
2013 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The occurrence of ARID1A mutations and alterations in the PI3K/AKT pathway in endometriosis and endometriosis-associated ovarian carcinomas, as well as the possible functional and clinical implications are discussed in this review.
|
24036443 |
2013 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.
|
31128298 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.
|
23869765 |
2013 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
This review focuses on recent research on the PI3K/AKT/mTOR pathway and its role in the progression and tumorigensis of ovarian cancer.
|
23591839 |
2013 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.
|
31284467 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in human ovarian cancer.
|
15806173 |
2005 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Many studies involving patients with cisplatin-resistant ovarian cancer have shown that AKT activation leads to inhibition of apoptosis.
|
27935869 |
2017 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The newly identified miR-99a/HOXA1/AKT/mTOR axis provides novel insight into the pathogenesis of ovarian cancer.
|
31210292 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results indicate that FAK inhibition can suppress ovarian cancer cells migration and invasion through inhibiting downstream signaling (PI3K/AKT), which might be a therapeutic target or biomarker for ovarian cancer.
|
24115647 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Moreover, VEGF expression could reverse the effect of miR-718 on ovarian cancer by increasing the levels of phosphorylated AKT.
|
24815691 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken all data together, these findings demonstrated that the absence of SMURF1 repressed cell proliferation, invasive capability, and EMT process in ovarian cancer through DAB2IP/AKT/Skp2 signaling loops, suggesting that SMURF1 may serve as a new potential therapeutic agent for ovarian cancer.
|
30672020 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
CTD_human |
Importantly, we found that ΔNp63α, AKT1, and phospho-AKT levels are greater in 2008CI3 CDDP-resistant ovarian cancer cells than in 2008 CDDP-sensitive cells. siRNA-mediated knockdown of ΔNp63α expression dramatically decreased AKT1 expression, whereas knockdown of either ΔNp63α or AKT1 decreased cell proliferation and increased death of ovarian and head/neck cancer cells.
|
21266360 |
2011 |
Malignant neoplasm of ovary
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The phosphatidylinositol 3-kinase (PI3K)/AKT pathway has been strongly implicated in the genesis of ovarian cancer.
|
17178867 |
2006 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Change in nm23-H1 expression and the PIK3/AKT pathway are involved in carcinogenesis, development, invasion and metastasis of ovarian cancers.
|
18949358 |
2008 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recently, a somatic mutation in AKT1 (E17K) has been detected in breast, colorectal, lung and ovarian cancers.
|
18504432 |
2008 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
SNHG16 may activate phosphorylation of AKT and upregulate the expression of MMP9 to promote cell proliferation, invasion and migration of ovarian cancer.
|
29461589 |
2018 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
High prevalence of genetic alterations in PI3K/AKT pathway in a Middle Eastern ovarian carcinoma provides genetic evidence supporting the notion that dysregulated PI3K/AKT pathways play an important role in the pathogenesis of ovarian cancers.
|
19638206 |
2009 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
|
25677064 |
2015 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The addition of VEGF, IGF-1, and IL-8 weakened the inhibitory effect of DIRAS3 on ERK/AKT activity and reduced DIRAS3-mediated TFEB or FOXo3a nuclear localization and MAPLC3B expression in ovarian cancer cells.
|
30620384 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.
|
25176450 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
An earlier study discovered an oncogenic AKT1 gene mutation (AKT1 E17K) in breast, colorectal and ovarian cancers.
|
18392055 |
2008 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR signaling pathway is considered as a promising therapeutic target in the treatment of ovarian cancer (OC); however, inhibition of this pathway only exhibited moderate clinical efficacy when tested clinically.
|
30972187 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
This is the first evidence that Tan-Ⅰ induced apoptosis and promoted autophagy via the inactivation of PI3K/AKT/mTOR pathway on ovarian cancer and further inhibited tumour growth, which might be considered as effective strategy.
|
31820522 |
2020 |